Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Change in Receivables (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Change in Receivables for 2 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 1478.31% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a N/A change, with the full-year FY2025 number at -$114936.0, up 61.59% from a year prior.
  • Change in Receivables was $1.1 million for Q4 2025 at Neuphoria Therapeutics, up from -$10190.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.1 million in Q4 2025 to a low of -$80399.0 in Q4 2024.